|
Parkinson's disease is the most common neurodegenerative disease after Alzheimer's, affecting at least 100,000 Canadians with the number of cases expected to double by the year 2050. While the ultimate cause of Parkinson's disease is unknown, symptoms are mainly thought to result from the death of brain cells that produce a chemical called dopamine.
The Parkinson Research Consortium (PRC) was formed in Ottawa in 2004 to bring together scientists with the common goals of understanding how and why these brain cells die, and applying this knowledge to the treatment of those with the condition.
There are presently no proven treatments available that can slow the relentless progression of the disease. Only through a better understanding of the basic mechanisms that cause it can effective disease-altering treatments be developed.
The PRC is composed of a select group of scientists from the Ottawa Hospital Research Institute (OHRI), the National Research Council and the University of Ottawa with diverse scientific talents and expertise in genetics, molecular biology, neuroscience and patient care. Our overall vision is to bring together a comprehensive group of individuals whose purpose is to eradicate a disease that currently follows an unremittingly, disabling course.
The Parkinson Research Consortium (PRC) is now just over three years old and continues to grow in productivity, personnel and resources to help find a cure for Parkinson's disease. Parkinson's disease is the second most common neurodegenerative disease that affects more than 1% of the population over 65 years old. Currently there are no treatments that have been shown to affect the progression of the disease. The PRC is composed of a select group of scientists at the Ottawa Hospital Research Institute and the University of Ottawa.
The main goal of the PRC is to be an incubator for innovative ideas in PD research and to generate novel findings leading to a cure for this devastating disease. It does so by promoting and encouraging synergistic interactions between scientists and clinicians. It also brings in specialists from other areas of neurobiology, cell biology, genetics and systems biology to study the problem of Parkinson's disease. Its secondary goals are to promote awareness in the local and national community as well as to promote integration of Parkinson's disease research on a national basis.
|
| |
